Lineage, Inc. Common Stock (LINE)vsSanofi ADR (SNY)
LINE
Lineage, Inc. Common Stock
$34.89
-1.30%
REAL ESTATE · Cap: $8.81B
SNY
Sanofi ADR
$46.03
+1.97%
HEALTHCARE · Cap: $109.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 772% more annual revenue ($46.72B vs $5.36B). SNY leads profitability with a 16.7% profit margin vs -1.9%. SNY earns a higher WallStSmart Score of 49/100 (D+).
LINE
Hold36
out of 100
Grade: F
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.03
$21.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -1.2% — below average capital efficiency
Revenue declined 0.2%
Distress zone — elevated risk
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bear Case : LINE
The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SNY is a mature play — different risk/reward profiles.
SNY is growing revenue faster at 6.9% — sustainability is the question.
SNY generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SNY scores higher overall (49/100 vs 36/100), backed by strong 16.7% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?